Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies.

Shahin Assefnia; Sivanesan Dakshanamurthy; Jaime M. Guidry Auvil; Constanze Hampel; Panos Z. Anastasiadis; Bhaskar Kallakury; Aykut Uren; David W. Foley; Milton L. Brown; Lawrence Shapiro; Michael Brenner; David Haigh; Stephen W. Byers

doi:10.18632/oncotarget.1538

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies.

Shahin Assefnia, Sivanesan Dakshanamurthy, Jaime M. Guidry Auvil, Constanze Hampel, Panos Z. Anastasiadis, Bhaskar Kallakury, Aykut Uren, David W. Foley, Milton L. Brown, Lawrence Shapiro, Michael Brenner, David Haigh and Stephen W. Byers _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2014; 5:1458-1474. https://doi.org/10.18632/oncotarget.1538

Metrics: PDF 4046 views | HTML 6024 views | ?

Abstract

Shahin Assefnia1,*, Sivanesan Dakshanamurthy1,*, Jaime M. Guidry Auvil1,*, Constanze Hampel1, Panos Z. Anastasiadis2, Bhaskar Kallakury1, Aykut Uren1, David W Foley4, Milton L. Brown5, Lawrence Shapiro6, Michael Brenner3, David Haigh4 and Stephen W. Byers1

1 The Georgetown-Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA

2 Department of Cancer Cell Biology, Mayo Clinic, Jacksonville, FL, USA

3 Department of Medicine, Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital, Boston, MA. USA

4 Center for Cancer Research and Cell Biology, School of Medicine, Dentistry and Biomedical sciences, Queen’s University Belfast, Northern Ireland, UK

5 Center for Drug Discovery, Georgetown University Medical Center,Washington, DC, USA

6 Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY, USA

* These authors contributed equally

Correspondence:

Stephen W. Byers, email:

Keywords: cadherin-11, breast cancer, glioblastoma, small molecule inhibitor, rheumatoid arthritis, celecoxib

Received: October 26, 2013 Accepted: November 14, 2013 Published: November 15, 2013

Abstract

Cadherin-11 (CDH11), associated with epithelial to mesenchymal transformation in development, poor prognosis malignancies and cancer stem cells, is also a major therapeutic target in rheumatoid arthritis (RA). CDH11 expressing basal-like breast carcinomas and other CDH11 expressing malignancies exhibit poor prognosis. We show that CDH11 is increased early in breast cancer and ductal carcinoma in-situ. CDH11 knockdown and antibodies effective in RA slowed the growth of basal-like breast tumors and decreased proliferation and colony formation of breast, glioblastoma and prostate cancer cells. The repurposed arthritis drug celecoxib, which binds to CDH11, and other small molecules designed to bind CDH11 without inhibiting COX-2 preferentially affect the growth of CDH11 positive cancer cells in vitro and in animals. These data suggest that CDH11 is important for malignant progression, and is a therapeutic target in arthritis and cancer with the potential for rapid clinical translation.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 1538

Publication Alerts

Research Papers:

Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies.

Abstract